To date, ACT has raised over $14 million and built a promising pipeline of potential breakthrough anti-cancer products entering human clinical trials.

ACT business model is to partner with commercial pharmaceutical companies prior to or at the completion of Phase 1 human clinical trials.

The Eighth Annual Shareholders meeting for 2017 has not yet been scheduled.

Advanced Cancer Therapeutics